Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. (Q54467741)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/24321804

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/24321804

chronic obstructive pulmonary disease

0 references

0 references

author name string

Claus F Vogelmeier

1

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/24321804

Eric D Bateman

2

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/24321804

John Pallante

3

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/24321804

Vijay K T Alagappan

4

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/24321804

Peter D'Andrea

5

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/24321804

Hungta Chen

6

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/24321804

Donald Banerji

7

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/24321804

publication date

6 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/24321804

The Lancet. Respiratory medicine

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/24321804

1

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/24321804

1

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/24321804

51-60

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/24321804

Inhaled corticosteroids in COPD: the case against

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal important difference of the transition dyspnoea index in a multinational clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Formoterol and tiotropium compared with tiotropium alone for treatment of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adverse skin reactions to inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Contemporary management of chronic obstructive pulmonary disease: scientific review

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of inhaled corticosteroids and the risk of cataracts.

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A systematic review of the associations between dose regimens and medication compliance

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of COPD: Relationships between daily dosing frequency, adherence, resource use, and costs

1 reference

https://api.crossref.org/works/10.1016%2FS2213-2600%2812%2970052-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S2213-2600(12)70052-8

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/24321804

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/24321804

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54467741&oldid=1419382550"